People news: JAMA, King Pharmaceuticals

Catherine DeAngelis will step down from her post as JAMA editor-in-chief next June, the journal said. During her 10-year career at the AMA-published medical publication, DeAngelis toughened conflict-of-interest guidelines, worked to require registration of clinical trials as a condition of publication and established the JAMA requirement that industry-sponsored clinical trials must have an independent academic statistician to review all data before a manuscript can be accepted and published. But she was also criticized for letting some author conflicts go undisclosed. Formerly a vice dean at the Johns Hopkins University School of Medicine, DeAngelis plans to return to the school to develop a Center for Professionalism in Medicine and the Related Professions. A search is on for her replacement, and a successor will be named by next July, the journal said. According to Kantar Media's Journal Ad Review, JAMA ranked second among medical/surgical publications by 2009 ad revenue, while ad pages fell 12.8% vs. 2008.

King Pharmaceuticals named Jeffrey Bailey chief commercial officer. Bailey joins the company from Novartis, where he was a general manager. He will be responsible for all commercial activities in branded pharma and will lead sales, marketing, managed care, sales operations and business analytics.